首頁 > 市場調查報告書 > 醫療設備

體外診斷感染疾病

市場調查報告書

商品編碼

1918267

尿道感染檢測市場－2026-2031年預測

Urinary Tract Infection Testing Market - Forecast from 2026 to 2031

出版日期: 2026年01月19日 | 出版商:

Knowledge Sourcing Intelligence | 英文 143 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計到 2025 年，尿道感染檢測市場規模將達到 723,625,000 美元，到 2031 年將達到 1,058,701,000 美元，複合年成長率為 6.55%。

尿道感染(UTI) 檢測市場涵蓋多種旨在檢測和識別泌尿系統（包括腎臟、輸尿管、膀胱和尿道）感染疾病的調查方法。檢測方法從傳統的尿液檢查和尿液培養到先進的快速診斷檢測、分子檢測和照護現場(POC) 設備，種類繁多。選擇合適的檢測方法取決於患者的症狀、病歷和臨床情況，始終以獲得準確且快速的結果為目標，從而指導有效的抗菌治療決策。

主要市場成長要素

市場擴張是由流行病學、人口統計和技術因素共同推動的，這些因素同時推動了檢測量的增加和更複雜的診斷方法。

全球尿道感染（UTI）的高發生率及其持續成長是推動市場需求的重要因素。泌尿道感染是最常見的細菌感染疾病之一，消耗了大量的醫療資源，涵蓋門診、急診和住院等各個環節。這種沉重的臨床負擔使得人們迫切需要可靠的診斷檢測方法來確診感染、指南適當的治療，並減少併發症和復發。

泌尿道感染的高發生率，加上民眾和臨床醫師對泌尿道感染症狀及及時診斷重要性的認知不斷提高，促使檢測量增加。教育宣傳活動和公共衛生訊息鼓勵儘早醫，這也促進了檢測量的增加。對於醫療服務提供者而言，認知的提高凸顯了準確診斷的必要性，以便將泌尿道感染與其他具有類似症狀的疾病區分開來，並促進了最佳的抗生素管理。

從人口統計學角度來看，人口老化是全球一項重要的趨勢，也是重要的成長要素。老年人，尤其是長期居住在護理機構的老年人，由於免疫功能老齡化成長而下降、合併糖尿病、尿失禁以及使用留置導尿管等因素，更容易發生尿路感染。此外，老年人的症狀通常不典型或特異性，因此需要降低診斷檢測的閾值，以避免漏診和尿膿毒症等嚴重後遺症。

技術進步與市場演變

塑造市場格局的關鍵趨勢之一是快速、高精度診斷技術的開發和廣泛應用。與需要 24-48 小時的傳統培養方法相比，市場明顯傾向於選擇能夠縮短檢測時間的解決方案。主要進展包括：

增強照護現場檢測 (POC)：可在幾分鐘內提供結果，為基層醫療和急診環境提供即時的臨床決策支援。
分子診斷檢測：利用 PCR 和多重檢測板，我們可以在數小時內鑑定病原體，特別是重要的抗菌素抗藥性標記，從而直接支持標靶治療。
自動化尿液分析系統：提高常規尿液篩檢的速度、一致性和定量準確性。

這些技術進步對於改善患者照護路徑、儘早開始適當治療以及支持更廣泛的抗菌藥物管理舉措至關重要。

主要市場挑戰

尿道感染檢測領域面臨的一大挑戰是全球抗菌素抗藥性（AMR）危機，而抗生素的過度使用是造成這場危機的部分原因。目前，對於疑似尿道感染，在未確診的情況下經驗性地使用抗生素的做法仍然十分普遍，這助長了抗藥性細菌的出現。這種情況對檢測市場提出了雙重要求：首先，提供快速且方便的診斷方法，以遏制不必要的抗生素使用；其次，研發能夠準確檢測抗藥性病原體的檢測方法，從而指導合理的治療。因此，先進檢測技術的成功與否，本質上取決於臨床行為向「檢測優先」模式的轉變。

區域市場展望

預計北美將繼續保持尿道感染檢測市場的主導地位。這主要歸功於該地區尿道感染報告發病率高、診斷基礎設施完善、醫療保健支出巨大以及對先進檢測技術的早期應用。此外，該地區人口老化嚴重以及法規結構健全，進一步增強了對常規和先進診斷解決方案的需求。

競爭格局與產品差異化

競爭格局包括眾多大型多元化診斷和專業生命科學公司。產品開發重點在於滿足關鍵市場需求：

速度和工作流程效率：我們提供一個整合系統，簡化從檢體到結果的測試流程，減少人工操作時間，提高檢查室吞吐量。
全面病原體鑑定：不僅限於簡單的檢測，還能從單一檢體中詳細鑑定多種泌尿道病原體。
抗生素抗藥性檢測：整合關鍵抗生素抗藥性標記（例如，ESBL、碳青黴烯酶基因）的檢測，以直接指導治療選擇和藥物管理工作。
照護現場近性：透過開發易於使用的、CLIA豁免的設備，在非檢查室環境中提供可靠的檢測結果，從而擴大檢測的可近性。

總之，尿道感染檢測市場正隨著持續的臨床需求和以診斷主導的抗生素合理使用的迫切需求而不斷發展。人口結構變化和技術創新是推動市場成長的關鍵因素，這些創新能夠提供更快、更準確的檢測結果。未來，快速、多重分子診斷能否成功整合到常規診療流程中，將決定市場的發展方向，使臨床醫師能夠快速、準確地做出治療決策。這種轉變不僅對改善個別患者的治療效果至關重要，而且在全球對抗抗菌素抗藥性的行動中也發揮關鍵作用。

本報告的主要優勢：

深入分析：取得以客戶群、政府政策和社會經濟因素、消費者偏好、垂直產業和其他細分市場為重點的深入市場洞察，涵蓋主要地區和新興地區。
競爭格局：了解主要企業採取的策略舉措，並了解透過正確的策略實現市場滲透的潛力。
市場促進因素與未來趨勢：探索動態因素和關鍵市場趨勢，以及它們將如何塑造未來的市場發展。
可執行的建議：利用洞察力為策略決策提供訊息，從而在動態環境中開拓新的業務管道和收入來源。
受眾範圍廣：對新興企業、研究機構、顧問公司、中小企業和大型企業都有益處且經濟高效。

它是用來做什麼的？

產業與市場洞察、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範及其影響、新產品開發、競爭影響

分析範圍

歷史資料（2021-2025 年）和預測資料（2026-2031 年）
成長機會、挑戰、供應鏈前景、法規結構、客戶行為和趨勢分析
競爭對手定位、策略和市場佔有率分析
按業務板塊和地區（國家）分類的收入成長和預測分析
公司概況（策略、產品、財務資訊、關鍵趨勢等）

The Urinary Tract Infection (UTI) testing market encompasses a range of diagnostic methodologies designed to detect and identify infections within the urinary system, including the kidneys, ureters, bladder, and urethra. Testing modalities vary from traditional urinalysis and urine culture to advanced rapid diagnostic tests, molecular assays, and point-of-care (POC) devices. The selection of an appropriate test is guided by patient symptomatology, medical history, and the clinical setting, with a constant focus on achieving accurate, timely results to inform effective antimicrobial therapy.

Primary Market Growth Drivers

Market expansion is propelled by a confluence of epidemiological, demographic, and technological factors that are increasing both the volume of testing and the sophistication of diagnostic approaches.

The high and increasing prevalence of UTIs globally is the fundamental demand driver. UTIs remain one of the most common bacterial infections, leading to significant healthcare utilization across outpatient, emergency department, and inpatient settings. This substantial clinical burden creates a continuous, high-volume need for reliable diagnostic testing to confirm infection, guide appropriate treatment, and help mitigate complications and recurrence.

Complementing this prevalence is a growing public and clinical awareness of UTI symptoms and the importance of timely diagnosis. Educational initiatives and public health messaging are encouraging individuals to seek medical evaluation earlier, which in turn drives testing volumes. For healthcare providers, heightened awareness underscores the need for accurate diagnostics to differentiate UTIs from other conditions with similar presentations, thereby optimizing antibiotic stewardship.

Demographically, the global trend of population aging is a significant growth catalyst. Older adults, particularly those in long-term care settings, exhibit increased susceptibility to UTIs due to factors such as immunosenescence, comorbid conditions (e.g., diabetes), urinary incontinence, and the use of indwelling catheters. Furthermore, presentations in the elderly can be atypical or non-specific, necessitating a lower threshold for diagnostic testing to avoid underdiagnosis and serious sequelae like urosepsis.

Technological Advancements and Market Evolution

A key trend shaping the market is the development and adoption of rapid and more precise diagnostic technologies. There is a clear shift toward solutions that reduce the time-to-result compared to standard culture methods, which can take 24-48 hours. Advancements include:

Enhanced Point-of-Care (POC) Tests: Providing results in minutes to guide immediate clinical decisions in primary care or emergency settings.
Molecular Diagnostic Assays: Utilizing PCR and multiplex panels to deliver pathogen identification and, critically, antimicrobial resistance markers within a few hours, directly supporting targeted therapy.
Automated Urinalysis Systems: Improving the speed, consistency, and quantitative accuracy of routine urine screening.

These technological advancements are critical for improving patient care pathways, enabling earlier initiation of correct therapy, and supporting broader antimicrobial stewardship initiatives.

Critical Market Challenges

A major challenge confronting the UTI testing landscape is the global crisis of antimicrobial resistance (AMR), fueled in part by antibiotic overuse. Empirical prescription of antibiotics for suspected UTIs without diagnostic confirmation remains common, contributing to resistance development. This environment creates a dual imperative for the testing market: first, to provide rapid, accessible diagnostics that can curb unnecessary antibiotic use; and second, to evolve tests that can accurately detect resistant pathogens to guide appropriate therapy. The success of advanced testing is, therefore, intrinsically linked to changing clinical behavior toward a "test-first" paradigm.

Geographic Market Outlook

North America is projected to maintain a dominant position in the UTI testing market. This is attributed to the region's high reported incidence of UTIs, a well-established diagnostic infrastructure, significant healthcare expenditure, and early adoption of advanced testing technologies. The presence of a large aging population and robust regulatory frameworks further solidify demand for both routine and sophisticated diagnostic solutions in this region.

Competitive Landscape and Product Differentiation

The competitive environment includes large, diversified diagnostic corporations and specialized life science firms. Product development is focused on addressing key market needs:

Speed and Workflow Efficiency: Offering integrated systems that streamline testing from sample to result, reducing hands-on time and improving laboratory throughput.
Comprehensive Pathogen Identification: Moving beyond simple detection to provide detailed identification of a broad panel of uropathogens from a single sample.
Resistance Detection: Integrating detection of key antibiotic resistance markers (e.g., ESBL, carbapenemase genes) to directly inform therapeutic choices and stewardship efforts.
Point-of-Care Accessibility: Developing easy-to-use, CLIA-waived devices that deliver reliable results in non-laboratory settings, expanding test access.

In conclusion, the UTI testing market is evolving in response to persistent clinical demand and the urgent need for diagnostic-driven antibiotic stewardship. Growth is underpinned by demographic shifts and technological innovation aimed at delivering faster, more informative results. The market's future trajectory will be defined by the successful integration of rapid, multiplexed molecular diagnostics into routine care pathways, empowering clinicians to make precise therapeutic decisions swiftly. This shift is essential not only for improving individual patient outcomes but also for playing a critical role in the global effort to combat antimicrobial resistance.

Key Benefits of this Report:

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data from 2021 to 2025 & forecast data from 2026 to 2031
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Urinary Tract Infection Testing Market Segmentation

By Infection Type
Urethritis
Cystitis
Pyelonephritis
By Test Type
Urinalysis
Urine Culture Test
Others
By End-User
Hospitals
Diagnostic Centers
Others
By Geography
North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
China
India
Japan
South Korea
Indonesia
Thailand
Others

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. URINARY TRACT INFECTION TESTING MARKET BY INFECTION TYPE

5.1. Introduction
5.2. Urethritis
5.3. Cystitis
5.4. Pyelonephritis

6. URINARY TRACT INFECTION TESTING MARKET BY TEST TYPE

6.1. Introduction
6.2. Urinanalysis
6.3. Urine Culture Test
6.4. Others

7. URINARY TRACT INFECTION TESTING MARKET BY END-USER

7.1. Introduction
7.2. Hospitals
7.3. Diagnostic Centers
7.4. Others

8. URINARY TRACT INFECTION TESTING MARKET BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. USA
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. Germany
- 8.4.2. France
- 8.4.3. United Kingdom
- 8.4.4. Spain
- 8.4.5. Others
8.5. Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Others
8.6. Asia Pacific
- 8.6.1. China
- 8.6.2. India
- 8.6.3. Japan
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others